[{"address1": "Times Square Tower", "address2": "Suite 2503 7 Times Square", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "646 200 5278", "website": "https://www.sellaslifesciences.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.", "fullTimeEmployees": 16, "companyOfficers": [{"maxAge": 1, "name": "Dr. Angelos M. Stergiou M.D., ScD h.c.", "age": 47, "title": "Founder, President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 904243, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John Thomas Burns CPA", "age": 38, "title": "Senior VP & CFO", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 505158, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stacy E. Yeung", "title": "VP, Associate General Counsel & Head of Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dragan  Cicic M.D., MBA", "age": 60, "title": "Senior Vice President of Clinical Development", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 466430, "exercisedValue": 0, "unexercisedValue": 55739}, {"maxAge": 1, "name": "Mr. Andrew  Elnatan", "title": "VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.2, "open": 1.22, "dayLow": 1.2, "dayHigh": 1.26, "regularMarketPreviousClose": 1.2, "regularMarketOpen": 1.22, "regularMarketDayLow": 1.2, "regularMarketDayHigh": 1.26, "beta": 2.392, "forwardPE": -2.9069767, "volume": 741271, "regularMarketVolume": 741271, "averageVolume": 605169, "averageVolume10days": 515380, "averageDailyVolume10Day": 515380, "bid": 1.23, "ask": 1.24, "bidSize": 100, "askSize": 100, "marketCap": 80415624, "fiftyTwoWeekLow": 0.5, "fiftyTwoWeekHigh": 1.72, "fiftyDayAverage": 1.2522, "twoHundredDayAverage": 1.14895, "currency": "USD", "enterpriseValue": 71960624, "floatShares": 64152367, "sharesOutstanding": 64332500, "sharesShort": 8176719, "sharesShortPriorMonth": 8215220, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.1271, "heldPercentInsiders": 0.00243, "heldPercentInstitutions": 0.0954, "shortRatio": 17.25, "shortPercentOfFloat": 0.1274, "bookValue": 0.05, "priceToBook": 25.0, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -34439000, "trailingEps": -0.94, "forwardEps": -0.43, "lastSplitFactor": "1:50", "lastSplitDate": 1573171200, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SLS", "underlyingSymbol": "SLS", "shortName": "SELLAS Life Sciences Group, Inc", "longName": "SELLAS Life Sciences Group, Inc.", "firstTradeDateEpochUtc": 1205328600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d5f0c150-9f89-3f17-8497-1832af4e7670", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.25, "targetHighPrice": 7.5, "targetLowPrice": 4.0, "targetMeanPrice": 5.83, "targetMedianPrice": 6.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 9147000, "totalCashPerShare": 0.142, "totalDebt": 692000, "quickRatio": 0.759, "currentRatio": 1.021, "debtToEquity": 23.756, "returnOnAssets": -1.2915199, "returnOnEquity": -8.8806095, "freeCashflow": -26447500, "operatingCashflow": -32160000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-17"}]